Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial

International Ophthalmology

Volumn 35, Issue 3, 2015, Pages 421-428

  Soheilian, Masoud ^a,b,c,d   Karimi, Saeed ^a,b,c,d   Ramezani, Alireza ^a,b,c,d   Montahai, Talieh ^a,b,c,d   Yaseri, Mehdi ^a,b,c,d   Soheilian, Roham ^a,b,c,d   Peyman, Gholam A ^a,b,c,d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Negah Eye Hospital   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab; Clinically significant diabetic macular edema; Diabetic retinopathy; Diclofenac

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANALYSIS OF VARIANCE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEVACIZUMAB; DIABETIC RETINOPATHY; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84938576003     PISSN: 01655701     EISSN: 15732630     Source Type: Journal    
DOI: 10.1007/s10792-014-9967-z     Document Type: Article

References (37)

1. Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91(1):1–9
2. Elman MJ, Aiello LP, Beck RW et al (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117(6):1064e35–1077e35
3. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115(9):1447–1449 9e1–10e1
4. Beck RW, Edwards AR, Aiello LP et al (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127(3):245–251
5. Cunningham ET Jr, Adamis AP, Altaweel M et al (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747–1757
6. Chun DW, Heier JS, Topping TM et al (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113(10):1706–1712
7. Haritoglou C, Kook D, Neubauer A et al (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26(9):999–1005
8. Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy. Dev Ophthalmol 39:122–148
9. Michaelides M, Kaines A, Hamilton RD et al (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 117(6):1078e2–1086e2
10. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H et al (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114(4):743–750
11. Nguyen QD, Shah SM, Heier JS et al (2009) Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116(11):2175e1–2181e1
12. Nguyen QD, Shah SM, Khwaja AA et al (2010) Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117(11):2146–2151
13. Soheilian M, Garfami KH, Ramezani A et al (2012) Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 32(2):314–321
14. Soheilian M, Ramezani A, Yaseri M et al (2011) Initial macular thickness and response to treatment in diabetic macular edema. Retina 31(8):1564–1573
15. Soheilian M, Ramezani A, Obudi A et al (2009) Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 116(6):1142–1150
16. Soheilian M, Ramezani A, Bijanzadeh B et al (2007) Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 27(9):1187–1195
17. Ahmadieh H, Ramezani A, Shoeibi N et al (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 246(4):483–489
18. Soheilian M, Karimi S, Ramezani A, Peyman GA (2010) Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 30(3):509–515
19. Soheilian M, Rabbanikhah Z, Ramezani A et al (2010) Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 26(2):199–206
20. Fine HF, Baffi J, Reed GF et al (2001) Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132(5):794–796
21. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD (2006) Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 142(1):192–194
22. Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47(Suppl 1):S203–S218
23. Elbendary AM, Shahin MM (2011) Intravitreal diclofenac versus intravitreal triamcinolone acetonide in the treatment of diabetic macular edema. Retina 31(10):2058–2064
24. Reis Ado C, Vianna RN, Reis RS, Cardoso GP (2010) Intravitreal injection of ketorolac tromethamine in patients with diabetic macular edema refractory to retinal photocoagulation. Arq Bras Oftalmol 73(4):338–342
25. Maldonado RM, Vianna RN, Cardoso GP et al (2011) Intravitreal injection of commercially available ketorolac tromethamine in eyes with diabetic macular edema refractory to laser photocoagulation. Curr Eye Res 36(8):768–773
26. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103(12):1796–1806
27. Chylack LT Jr, Leske MC, McCarthy D et al (1989) Lens opacities classification system II (LOCS II). Arch Ophthalmol 107(7):991–997
28. Joussen AM, Poulaki V, Mitsiades N et al (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16(3):438–440
29. Wilkinson-Berka JL (2004) Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 10(27):3331–3348
30. Preud’homme Y, Demolle D, Boeynaems JM (1985) Metabolism of arachidonic acid in rabbit iris and retina. Invest Ophthalmol Vis Sci 26(10):1336–1342
31. Naveh N, Peer J, Bartov E, Weissman C (1991) Argon laser irradiation of rabbits’ eyes-changes in prostaglandin E2 levels. Prostaglandins 41(2):143–155
32. Cheng T, Cao W, Wen R et al (1998) Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci 39(3):581–591
33. Callanan D, Williams P (2008) Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol 2(4):689–692
34. Endo N, Kato S, Haruyama K et al (2010) Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol 88(8):896–900
35. Kim SJ, Adams NA, Toma HS et al (2008) Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 28(4):595–605
36. Shimura M, Nakazawa T, Yasuda K, Nishida K (2007) Diclofenac prevents an early event of macular thickening after cataract surgery in patients with diabetes. J Ocul Pharmacol Ther 23(3):284–291
37. Durairaj C, Shah JC, Senapati S, Kompella UB (2009) Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 26(5):1236–1260